MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
26.46
-0.48
-1.78%
After Hours: 26.46 0 0.00% 16:04 07/11 EDT
OPEN
26.50
PREV CLOSE
26.94
HIGH
26.89
LOW
25.91
VOLUME
54.66K
TURNOVER
--
52 WEEK HIGH
29.27
52 WEEK LOW
6.20
MARKET CAP
292.53M
P/E (TTM)
-3.8374
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PVLA last week (0630-0704)?
Weekly Report · 5d ago
Palvella Therapeutics to join Russell 3000 and Russell 2000 Indexes
Seeking Alpha · 06/30 11:45
Weekly Report: what happened at PVLA last week (0623-0627)?
Weekly Report · 06/30 09:53
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Barchart · 06/30 06:30
Scotiabank Remains a Buy on Palvella Therapeutics (PVLA)
TipRanks · 06/27 11:16
Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
TipRanks · 06/24 11:35
Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
TipRanks · 06/23 17:04
Palvella Completes Enrollment In Phase 3 SELVA Trial Of QTORIN Rapamycin For Microcystic Lymphatic Malformations, Exceeding Target Of 40 Subjects By Over 25%
Benzinga · 06/23 11:32
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.